Relationships between genetic polymorphisms and transcriptional profiles for outcome prediction in anticancer agent treatment
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
In the era of personal genomics, predicting the individual response to drug-treatment is a challenge of biomedical research. The aim of this study was to validate whether interaction information between genetic and transcriptional signatures are promising features to predict a drug response. Because drug resistance/susceptibilities result from the complex associations of genetic and transcriptional activities, we predicted the inter-relationships between genetic and transcriptional signatures. With this concept, captured genetic polymorphisms and transcriptional profiles were prepared in cancer samples. By splitting ninety-nine samples into a trial set (n = 30) and a test set (n = 69), the outperformance of relationship-focused model (0.84 of area under the curve in trial set, P = 2.90 × 10-4) was presented in the trial set and validated in the test set, respectively. The prediction results of modeling show that considering the relationships between genetic and transcriptional features is an effective approach to determine outcome predictions of drug-treatment.
Abstract
In the era of personal genomics, predicting the individual response to drug-treatment is a challenge of biomedical research. The aim of this study was to validate whether interaction information between genetic and transcriptional signatures are promising features to predict a drug response. Because drug resistance/susceptibilities result from the complex associations of genetic and transcriptional activities, we predicted the inter-relationships between genetic and transcriptional signatures. With this concept, captured genetic polymorphisms and transcriptional profiles were prepared in cancer samples. By splitting ninety-nine samples into a trial set (n = 30) and a test set (n = 69), the outperformance of relationship-focused model (0.84 of area under the curve in trial set, P = 2.90 × 10-4) was presented in the trial set and validated in the test set, respectively. The prediction results of modeling show that considering the relationships between genetic and transcriptional features is an effective approach to determine outcome predictions of drug-treatment.
참고문헌 (22)
- Yap, T. A., "Beyond chemotherapy: targeted therapies in ovarian cancer", Nat. Rev. Cancer, 9, pp.167~181 (2009)
- Jemal, A., "Cancer statistics, 2008", CA Cancer J. Clin., 58, pp.71~96 (2008)
- Santos, A. M., "TP53 and P21 polymorphisms: response to cisplatinum", paclitaxel-based chemotherapy in ovarian cancer, 2006, pp.340, 256~262
- Fuchs, D., "Salinomycin overcomes ABC transportermediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells", Biochem. Biophys. Res. Commun., 394, pp.1098~1104 (2010)
- Judson, P. L., "Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy", Cancer Res., 59, pp.2425~2432 (1999)
- Denkert, C., "A prognostic gene expression index in ovarian cancer - validation across different independent data sets", J. Pathol., 218, pp.273~280 (2009)
- Sabatier, R., "Gene expression profiling and prediction of clinical outcome in ovarian cancer", Crit. Rev. Oncol. Hematol., 72, pp.98~109 (2009)
- Hartmann, L. C., "Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy", Clin. Cancer Res., 11, pp.2149~2155 (2005)
- Kim, H. S., "Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study", Gynecol. Oncol., 113, pp.264~269 (2009)
- Green, H., "mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T", A correlates with response to paclitaxel chemotherapy, 2006, pp.12, 854~859
- Marsh, S., "Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer", J. Clin. Oncol., 25, pp.4528~4535 (2007)
- Huang, R. S., "Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach", Am. J. Hum. Genet., 81, pp.427~437 (2007)
- Li, J., "Genetical genomics: combining genetics with gene expression analysis", Hum. Mol. Genet., 14(2), pp.R163~R169 (2005)
- Kamazawa, S., "Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer", Gynecol. Oncol., 86, pp.171~176 (2002)
- Perek, N., "MRP-1 protein expression and glutathione content of in vitro tumor cell lines derived from human glioma carcinoma U-87-MG do not interact with 99mTc-glucarate uptake", Cancer Biother. Radiopharm., 20, pp.391~400 (2005)
- Yamaguchi, H., "Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer", Int. J. Gynecol. Cancer, 16, pp.979~985 (2006)
- Knaus, W. A., "The clinical evaluation of new drugs for sepsis. A prospective study design based on survival analysis", JAMA, 270, pp.1233~1241 (1993)
- Heagerty, P. J., "Timedependent ROC curves for censored survival data and a diagnostic marker", Biometrics, 56, pp.337~344 (2000)
- Zaman, G. J., "The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump", Proc. Natl. Acad. Sci. U.S.A., 통권 : 91, pp.8822~8826 (1994)
- Wagner, P., "Microtubule Associated Protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo", Cell Cycle, 4, pp.1149~1152 (2005)
- Gang Bai, "Promoter demethylation mediates the expression of ZNF645, a novel cancer", testis gene, 2010, pp.43(6), 400~406[DOI]
- Tregouet, D. A., "Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease", Nat. Genet., 41, pp.283~285 (2009)